Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics

Pediatric Pulmonology
Jennifer L Goralski, Stephanie D Davis

Abstract

While a major target in cystic fibrosis (CF) research in recent years has been the development of corrector and potentiator drugs targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein, these therapies have not yet proven robust enough to replace or eliminate other therapies that have demonstrated improved health outcomes and quality of life in patients with CF. Further, ivacaftor is only indicated for approximately 5% of the US CF population, although the FDA has recently approved lumacaftor/ivacaftor, a combination therapy intended for those homozygous for Phe508del, which should reach a much larger number of patients. This review appraises therapeutics currently available or being studied while we await the next generation of CFTR potentiators and correctors.

References

Feb 16, 1991·Lancet·N G McElvaneyR G Crystal
Mar 30, 1995·The New England Journal of Medicine·M W KonstanP B Davis
May 1, 1996·American Journal of Respiratory and Critical Care Medicine·M RobinsonP T Bye
Dec 18, 2001·The Journal of Pediatrics·J M QuanUNKNOWN Pulmozyme Early Intervention Trial Study Group
Oct 2, 2003·JAMA : the Journal of the American Medical Association·Lisa SaimanUNKNOWN Macrolide Study Group
Dec 8, 2004·Journal of Clinical Microbiology·Richard J Gillis, Barbara H Iglewski
Jan 20, 2006·The New England Journal of Medicine·Mark R ElkinsUNKNOWN National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group
Jan 20, 2006·The New England Journal of Medicine·Scott H DonaldsonRichard C Boucher
Aug 28, 2007·The Journal of Pediatrics·Larry C LandsMary Corey
Sep 18, 2007·American Journal of Respiratory and Critical Care Medicine·Michael W KonstanPamela B Davis
Oct 30, 2007·The Journal of Otolaryngology·D Richard LindstromWilliam M Gershan
Dec 7, 2007·The European Respiratory Journal·E DaviskasI H Young
Mar 15, 2008·Chest·Anna JaquesBrett Charlton
Jul 29, 2008·American Journal of Respiratory and Critical Care Medicine·Karen S McCoyA Bruce Montgomery
Oct 2, 2008·Pediatric Pulmonology·Elisabeth P DellonStephanie D Davis
Nov 10, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Don HayesDavid J Feola
Oct 22, 2010·Pediatric Pulmonology·Michael W KonstanGerhild Angyalosi
Nov 16, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Michael W KonstanDavid E Geller
Feb 15, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Nikola MarjanovićVesna Eraković Haber
Mar 26, 2011·Pediatric Pulmonology·Michael W KonstanUNKNOWN Scientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis
Mar 29, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·C E WainwrightA B Montgomery
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·David E GellerUNKNOWN Mpex 204 Study Group
Apr 12, 2011·The European Respiratory Journal·D BiltonUNKNOWN CF301 Study Investigators
Jul 26, 2011·The Journal of Antimicrobial Chemotherapy·Christopher M OermannA Bruce Montgomery
Aug 5, 2011·Pediatric Pulmonology·Gregory S SawickiLizheng Shi
Sep 7, 2011·Archives of Pediatrics & Adolescent Medicine·Miriam M TreggiariUNKNOWN Early Pseudomonas Infection Control (EPIC) Investigators
Nov 19, 2011·American Journal of Respiratory and Critical Care Medicine·Bruce C TrapnellUNKNOWN Phase 2 FTI Study Group
Dec 27, 2011·American Journal of Respiratory and Critical Care Medicine·Moira L AitkenUNKNOWN CF302 Investigators
May 23, 2012·JAMA : the Journal of the American Medical Association·Margaret RosenfeldUNKNOWN ISIS Study Group
Jun 22, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Kavi J LittlewoodGerhild Angyalosi
Jul 6, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·M ProesmansK De Boeck
Sep 19, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Baroukh M AssaelUNKNOWN AZLI Active Comparator Study Group
Sep 22, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Richard B MossUNKNOWN CF2110399 Investigators
Dec 14, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Diana BiltonUNKNOWN CF301 and CF302 Investigators
Apr 2, 2013·American Journal of Respiratory and Critical Care Medicine·Peter J MogayzelUNKNOWN Pulmonary Clinical Practice Guidelines Committee
Apr 4, 2013·Current Molecular Pharmacology·Mike Althaus
May 2, 2013·American Journal of Respiratory and Critical Care Medicine·Matthias GrieseAndreas Hector

❮ Previous
Next ❯

Citations

Dec 15, 2015·Pediatric Pulmonology·Maristella SantiSebastiano A G Lava
Sep 24, 2016·Pediatric Pulmonology·Cameron L JordanMarianna M Henry

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Verena I SeligerPeter Mueller
The New England Journal of Medicine
Bonnie W RamseyVX08-770-102 Study Group
© 2021 Meta ULC. All rights reserved